Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes - A prospective study

Annals of Transplantation

Volumn 19, Issue 1, 2014, Pages 32-40

  Steinebrunner, Niels ^a   Sandig, Catharina ^a   Sommerer, Claudia ^a   Hinz, Ulf ^a   Giese, Thomas ^b   Stremmel, Wolfgang ^a   Zahn, Alexandra ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute rejection episodes; Calcineurin inhibitors; Liver transplantation; NFAT regulated gene expression; Pharmacodynamic drug monitoring

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG DOSE COMPARISON; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION; HUMAN; LIVER GRAFT; LIVER GRAFT REJECTION; MALE; PHARMACODYNAMICS; PROSPECTIVE STUDY;

ACUTE DISEASE; ADULT; AGED; CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; FEMALE; GENE EXPRESSION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84893417691     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.889809     Document Type: Article

References (35)

1. Hariharan S, Johnson CP, Bresnahan BA et al: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med, 2000; 342: 605-12.
2. Waki K: UNOS Liver Registry: ten year survivals. Clin Transpl, 2006: 29-39.
3. Taylor AL, Watson CJ, Bradley JA: Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol, 2005; 56: 23-46.
4. Sommerer C, Meuer S, Zeier M, Giese T: Calcineurin inhibitors and NFAT-regulated gene expression. Clin Chim Acta, 2012; 413: 1379-1386.
5. Ojo AO, Held PJ, Port FK et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 2003; 349: 931-940.
6. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med, 1994; 331: 1110-1115.
7. Buell JF, Gross TG, Woodle ES: Malignancy after transplantation. Transplantation, 2005; 80: S254-S264.
8. de Groen PC, Aksamit AJ, Rakela J et al: Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med, 1987; 317: 861-866.
9. Hoorn EJ, Walsh SB, McCormick JA et al: The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med, 2011; 17: 1304-1309.
10. Wysocki GP, Gretzinger HA, Laupacis A et al: Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol, 1983; 55: 274-278.
11. Fernandez-Marmiesse A, Hermida J, Tutor JC: Comparison of predose vs. 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients. Clin Biochem, 2000; 33: 383-386.
12. Morris RG, Russ GR, Cervelli MJ et al: Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit, 2002; 24: 479-86.
13. Barnard JB, Thekkudan J, Richardson S et al: Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant, 2006; 25: 564-568.
14. Giese T, Zeier M, Schemmer P et al: Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation, 2004; 77: 339-344.
15. Zahn A, Schott N, Hinz U et al: Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transpl, 2011; 17: 466-473.
16. Sommerer C, Konstandin M, Dengler T et al: Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation, 2006; 82: 1280-1285.
17. Konstandin MH, Sommerer C, Doesch A et al: Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int, 2007; 20: 1036-1043.
18. Marin JG, Levine M, Ensom MH: Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit, 2006; 28: 637-642.
19. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med, 2004; 351: 2715-2729.
20. Sommerer C, Giese T, Meuer S, Zeier M: Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant, 2009; 24: 21-27.
21. van Rossum HH, Press RR, den Hartigh J, de Fijter JW: Point: A call for advanced pharmacokinetic and pharmacodynamic monitoring to guide calcineurin inhibitor dosing in renal transplant recipients. Clin Chem, 2010; 56: 732-735.
22. Marquet P: Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary? Clin Chem, 2010; 56: 736-739.
23. Stein CM, Murray JJ, Wood AJ: Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem, 1999; 45: 1477-1484.
24. Boleslawski E, Conti F, Sanquer S et al: Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation, 2004; 77: 1815-1820.
25. de Jonge H, Naesens M, Kuypers DR: New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit, 2009; 31: 416-435.
26. Burkhart C, Heusser C, Morris RE et al: Pharmacodynamics in the development of new immunosuppressive drugs. Ther Drug Monit, 2004; 26: 588-592.
27. Sommerer C, Zeier M, Meuer S, Giese T: Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation, 2010; 89: 1417-1423.
28. Sommerer C, Hartschuh W, Enk A et al: Pharmacodynamic immune monitoring of NFATregulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant, 2008; 22: 549-554.
29. Billing H, Breil T, Schmidt J et al: Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients. Pediatr Transplant, 2012; 16: 187-194.
30. Giese T, Zeier M, Meuer S: Analysis of NFATregulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol -Dial Transplant, 2004; 19(Suppl.4): iv55-iv60.
31. Herden U, Kromminga A, Hagel C et al: Monitoring of nuclear factor of activated T-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine a. Ther Drug Monit, 2011; 33: 185-191.
32. Neil DA, Hubscher SG: Current views on rejection pathology in liver transplantation. Transpl Int, 2010; 23: 971-983.
33. Cakaloglu Y, Devlin J, O'Grady J et al: Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation, 1995; 59: 40-45.
34. Anand AC, Hubscher SG, Gunson BK et al: Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation, 1995; 60: 1098-1103.
35. Ramji A, Yoshida EM, Bain VG et al: Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl, 2002; 8: 945-951